Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of RVT-1401 in warm autoimmune hemolytic anemia
MOH_2020-06-22_008636Phase 2Not yet recruiting
- Sponsor
- Immunovant, Inc.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of batoclimab in warm autoimmune hemolytic anemia (wAIHA) (2 arms), sponsored by Immunovant, Inc. Primary endpoints: Safety and tolerability, Pharmacokinetics and 2 more. Planned start May 2020; status: not yet recruiting.
02
Drugs
batoclimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on MOH_2020-06-22_008636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-22_008636.